Introduction: Currently there are no established guidelines regarding the use of long-chain triglycerides (LCT) vs. medium-chain triglycerides medium-chain triglycerides (MCT)/long-chain triglycerides (LCT) in total parenteral nutrition (TPN). Severe malnutrition of patients with refractory cachexia (RC) often causes their disqualification from invasive methods of treatment thus decreasing their quality of life and survival time.
Introduction
Currently, artificial nutrition of patients with refractory cachexia (RC) is not standard in palliative care [1] . Although nutritional support cannot reverse the body mass loss (BML) in this advanced stage, it can slow the rate of BML and improve the patient's physical abilities and quality of life [2, 3] . It is accepted that the survival time of palliative care patients is less than 3 months, while for terminal care patients it is less than 1 month. Therefore, the decisions regarding these patients' nutritional and hydration support must be made individually [4, 5] . Improving the nutritional state is a key element of palliative care, with the aim to alleviate the disease symptoms and increase the survival time of oncological patients [6, 7] .
The European Society for Clinical Nutrition and Metabolism (ESPEN) guidelines do not recommend nutri-tional therapy of cancer patients who have an intact ability to eat [8] . This recommendation is general and does not apply to patients who are unable to eat due to gastrointestinal tract (GIT) obstruction or semi-obstruction. Such patients require procedures that allow enteral nutrition (EN), e.g. stent in the area of the tumour, percutaneous endoscopic gastrostomy (PEG) placement, or percutaneous ileostomy. If such procedures are not technically possible or contraindicated, the patients can be offered a tumour bypass operation, surgical gastrostomy, or feeding jejunostomy below the tumour. Undernutrition, dehydration, and advanced tumour increase the risk of post-operative complications, although this can be reduced by using parenteral nutrition (PN) for 7-10 days pre-operatively [9] . Immunonutrition may boost the reduced immune response of such patients [10] . Unfortunately, the results of clinical trials regarding n-3 polyunsaturated fatty acid (PUFA) supplementation are equivocal [11] [12] [13] .
Aim
Our study had two aims: to compare the changes in nutritional state of patients with RC receiving PN with long-chain triglycerides (LCT) and LCT/medium-chain triglycerides (MCT) lipid emulsions and to assess the influence of EN on their survival time.
Material and methods
This clinical trial included 50 patients (23 female, 27 male), median age 65 ±11 years, with GIT cancer and RC. In terms of BML, body mass index (BMI), age, and sex there were no statistically significant differences between the patients in the LCT vs. MCT/LCT groups (Table I) .
Inclusion criteria: -Cancer diagnosis confirmed by pathological report, -Disqualified from oncological treatment due to advanced stage of cancer and/or poor overall condition, -Indications for nutritional support defined by Nutritional Risk Score (NRS 2002) ≥ 3 points, -Primary or secondary tumour or metastasis causing a GIT obstruction or semi-obstruction that prevents meeting the protein-energy demand via oral route, -Contraindications to or technical problems with PEG tube placement or other minimally-invasive methods of accessing the GIT, -Open surgery as the only means of restoring enteral feeding (via gastrostomy or feeding jejunostomy, exploratory laparotomy, colostomy, or anastomosis bypassing the obstruction). Exclusion criteria: -Contraindications to general anaesthesia, -Active inflammatory process (e.g. pneumonia, urinary tract infection), -Comorbidities causing significant metabolic disturbances (e.g. diabetes, liver cirrhosis).
On the day of admission, each patient had a central venous access placed while in the operating room. Next, the patients were assigned into one of two groups and perioperatively received either LCT emulsion (n = 30) or LCT/MCT (50 : 50) (n = 20). Patients who were included in this study were not informed which lipid emulsion they will receive. The emulsions were assigned to the patients using an online random number generator (http://www.randomizer.org/). The researchers knew, but had no influence on the type of administered substance. Based on the randomly generated list, patients received the mixture based on "0" corresponding to the LCT mixture and "1" to MCT/LCT. TPN was administered for 5 days pre-op, withdrawn on the day of operation, and then re-administered postop (modified according to the increase of EN and decrease of PN, with constant total amount of kcal per day).
Blood samples (2 ml each) were collected from the patients' ulnar veins in this sequence: -1 st sample -during the 1 st day of hospitalisation, -2 nd sample -6 th day of hospitalisation (5 th day of TPN), -3 rd sample -7 th day of hospitalisation (1 st day post-op, 6 th day of TPN), -4 th sample -11 th day of hospitalisation. The following blood parameters were measured: albumin, prealbumin, lymphocytes, total protein, and C-reactive protein (CRP).
Statistical analysis
Patient mortality was determined by accessing the official governmental death registry (44 of 50 patients). Statistical analysis was performed using Statistica software (version 10, StatSoft; Tulsa, OK). The influence of particular lipid emulsions on the examined clinical markers (blood samples 1-4) was analysed using the sign test for paired data. The correlations between the markers in both patient groups were measured using the Mann-Whitney U test. Survival was analysed with Kaplan Meier and log rank tests. Value of p < 0.05 was set as statistically significant.
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Ethics
Permission of the Independent Bioethics Committee for Scientific Research at the Medical University of Gdansk was obtained prior to the start of this study. All patients were notified about the aims of this study and gave their informed consent to participate. Due to ethical concerns, this study did not include a control group in nobody underwent surgical intervention, despite having possible benefit from surgical access to the GIT.
This
Results
In 78% of the patients the passage of food was obstructed by a primary GIT tumour, whereas in the remaining 22% by infiltration or metastasis from other organs (Table II) .
In all patients the diagnosis of cancer was made based on histopathological testing. In 8% of the patients it was not possible to locate the primary focus of cancer and the diagnosis was made based on samples of metastatic tissue. In 67% of the patients the ECOG/WHO/Zubrod score was assessed at 4 points and in 33% it was 3 points [14] . The following surgical procedures were performed: gastrostomy or feeding jejunostomy (58%), anastomosis bypassing the obstruction (20%), colostomy (12%), palliative gastrectomy (1%), and exploratory laparotomy in the remaining.
The relationship between the studied parameters and survival of patients
The mean post-op survival time of all patients was 192 ±268 days and the median was 98 days. Fifty-seven percent of studied patients survived > 90 days. The analysis showed that there is a statistical relationship only between CRP (p < 0.007) and the probability of survival over 90 days, but there is no relationship between the parameters of nutritional status and the probability of survival over 90 days (Figures 1 and 2) . BML > 15% BML < 15%
The influence of MCT/LCT emulsions vs. LCT on changes in the concentrations of markers of nutritional status
In both patient groups the levels of nutrition status markers significantly decreased between the time of 1 st and 4 th blood sample collections (Table III) . The extent of this decrease was similar in both groups. The CRP levels increased significantly but more so in the MCT/ LCT group (p < 0.042).
Discussion
The EPCRC (European Palliative Care Research Collaborative) emphasises that the reversal of BML in patients in the RC stage is not possible, regardless of the type and contents of nutritional mixture administered [15] . Blum et al. suggested specific criteria to distinguish particular stages of cancer cachexia and defined RC as BWL > 15% in the last 6 months and BMI < 23 kg/m 2 or BWL > 20% in the last 6 months and BMI < 27 kg/m 2 [16] . However, our results do not support their concepts.
The BML of patients with solid tumour of the GIT causing obstruction/semi-obstruction is a result not of cancer cachexia alone, but of both cancer cachexia and simple undernutrition [17] . Due to heavy reliance on BML, these patients may be too hastily diagnosed as being in the RC stage. That in turn may lead to depriving these patients of potentially beneficial surgical restoration of EN. A commonly accepted mean survival time of palliative care patients is 90 days. Whereas the mean survival time of the patients in our study was 192 days thanks to the surgical GIT access allowing EN. The lack of correlation between BML and expected survival time > 90 days suggests individual consideration of these patients [18, 19] .
Selection of the optimal contents of a nutritional mixture and artificial diet for cancer cachexia patients is still an unsolved problem. It is recommended that the lipids/glucose ratio in the nutrition of oncological patients be increased; however, these recommendations do not specify which fatty acids [20] . Long-chain fatty acids (LCFA) require L-carnitine as a transporter into the mitochondrial matrix, while the MCT do not. The L-carnitine concentration in the skeletal muscles and serum is reduced below reference values in CC patients due to the rate of skeletal muscle degradation (secondary to reduced dietary intake of L-carnitine) and loss in urine [21] . The serum L-carnitine deficiency is replenished from muscle storage after some delay [22] . In theory, mixing LCT and MCT lipid mixtures should improve the energy efficiency of fatty acid metabolism. However, our results and previous literature do not support this hypothesis [23] [24] [25] .
The heart and skeletal muscles contain 98% of the body's L-carnitine, which in a 70-kg male amounts to about 100 mmol. Taking into consideration the lack of dietary intake and 24-hour loss in urine, that amount of L-carnitine should suffice for about 660 days [26, 27] . It is possible that the L-carnitine pool ensures that the β-oxidation of LCFA takes place in muscles for a longer time than the expected survival time of RC patients. This may be the reason why there is no difference between the influence of MCT/LCT and LCT-only mixtures on the nutritional markers. The immune system cells do not store L-carnitine but gather it from the serum. That is why in state of reduced serum L-carnitine, the MCT/LCT emulsions may provide the immune cells with more energy than LCT-only and improve their response to inflammation [28] .
Conclusions
Our results do not indicate the superiority of use of MCT/LCT or LCT lipid emulsions in PN for patients with cancer cachexia. Simple undernutrition plays an important role in premature RC recognition in patients with a tumour causing gastrointestinal obstruction or semi-obstruction. The BML lacks prognostic value regarding the survival time in this patient group. Such patients require an individual treatment approach because some of them might benefit from invasive methods of restoring feeding. The lack of verified markers makes it difficult to distinguish the various stages of cachexia in clinical practice.
